New hope for myelofibrosis patients: drug combo trial targets those failed by standard therapy
NCT ID NCT06887803
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-stage trial tests a new drug called roginolisib combined with the standard drug ruxolitinib in 26 adults with myelofibrosis whose disease did not respond to approved JAK inhibitors. The main goal is to check the safety and tolerability of the combination. Researchers will also look at how the treatment affects spleen size and certain immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat
RECRUITINGBarcelona, 08908, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia
RECRUITINGFlorence, Florence, 50134, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Azienda Sanitario Universitaria Friuli Centrale
RECRUITINGUdine, 33100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Belfast City Hospital
NOT_YET_RECRUITINGBelfast, BT9&AB, United Kingdom
Contact Email: •••••@•••••
-
Guy´s and St. Thomas NHS Foundation Trust
NOT_YET_RECRUITINGLondon, SE1 9RT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario de Salamanca
RECRUITINGSalamanca, 37007, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IRCCS Clinical Institute Humanitas
RECRUITINGRozzano, Milan, 20089, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Istituto di Ematolgia e Oncologia Medica
RECRUITINGBologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Madrid CIOCC
NOT_YET_RECRUITINGMadrid, 28050, Spain
Contact Email: •••••@•••••
-
United Lincolnshire Teach Hospitals NHS Trust, Pilgrim Hospital Boston
NOT_YET_RECRUITINGBoston, Lincolnshire, PE21 9QS, United Kingdom
Contact Email: •••••@•••••
-
Vall d'Hebron University Hospital
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.